# Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)

> **NCT02320604** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Morbid Obesity

## Interventions

- **DRUG:** Administration of study drug

## Key facts

- **NCT ID:** NCT02320604
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2018-11-03
- **Final completion:** 2018-11-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320604, "Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02320604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*